

[Procarbazine](#)

Not recommended as an essential medicine

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01XB01](#)

Indication

Unspecified malignant neoplasms of ill-defined or unspecified sites ICD11 code: [2D9Z](#)

INN

Procarbazine

Medicine type

Chemical agent

List type

Complementary

Formulations

Oral > Solid: 50 mg (as hydrochloride)

EML status history

First added in 1979 ([TRS 641](#))

Changed in 2002 ([TRS 914](#))

Changed in 2007 ([TRS 950](#))

Changed in 2011 ([TRS 965](#))

Changed in 2015 ([TRS 994](#))

Removed in 2019 ([TRS 1021](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Procarbazine](#)

[DrugBank](#)

[Procarbazine](#)

Summary of evidence and Expert Committee recommendations

Listing for procarbazine was amended in 2019 to make an indication-specific reference to use in the treatment of Hodgkin lymphoma. Refer to the 2019 recommendation for procarbazine for more information.